Trial Outcomes & Findings for Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair (NCT NCT01912950)

NCT ID: NCT01912950

Last Updated: 2023-02-21

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

11 participants

Primary outcome timeframe

12-weeks

Results posted on

2023-02-21

Participant Flow

Unit of analysis: areas on the forearm

Participant milestones

Participant milestones
Measure
All Study Participants
Each subject will receive hair removal treatments with the Prowave LX IPL. Each subject will have one designated treatment area on the foreman and one un-treated control area.
Overall Study
STARTED
11 22
Overall Study
Treated Areas on the Forearm
11 11
Overall Study
Untreated Areas on the Forearm
11 11
Overall Study
COMPLETED
7 14
Overall Study
NOT COMPLETED
4 8

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Enrolled Subjects
n=11 Participants
All enrolled subjects receiving treatment
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
9 Participants
n=5 Participants
Sex: Female, Male
Male
2 Participants
n=5 Participants
Region of Enrollment
United States
11 participants
n=5 Participants

PRIMARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Prowave LX IPL
n=7 Participants
Treatment with Prowave LX IPL
No Treatment
n=7 Participants
No treatment administered
Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment
41 percent reduction
Interval -62.0 to 97.0
27 percent reduction
Interval -60.0 to 85.0

Adverse Events

Prowave LX IPL

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

No Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Prowave LX IPL
n=11 participants at risk
Prowave LX IPL on one area of the forearm
No Treatment
n=11 participants at risk
No treatment administered.
Skin and subcutaneous tissue disorders
Erythema
45.5%
5/11 • 12 weeks
0.00%
0/11 • 12 weeks
Skin and subcutaneous tissue disorders
Edema
9.1%
1/11 • 12 weeks
0.00%
0/11 • 12 weeks

Additional Information

Margot Doucette

Cutera

Phone: 415-657-5518

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place